Sleep Apnea Drug Pipeline Has Expanded Rapidly
More than two dozen new treatments are in development for sleep apnea, potentially offering future oral alternatives.
Updated on Sept. 23, 2026 in Sleep Disorders
Live Poll
Will new pharmacological treatments lead to better long-term management for sleep apnea patients?
A new industry analysis from DelveInsight reveals that over 22 companies are currently developing 24 or more sleep apnea drugs. This shift toward pharmacological interventions could broaden treatment options for patients beyond existing standard therapies.
Why it matters
The development landscape is moving toward a more diversified market, with an increasing focus on oral medications and GLP-1-based therapies to address obesity-associated sleep apnea. These advancements aim to provide more patient-specific options for those struggling with traditional management.
A pipeline analysis identifies over 24 sleep apnea drug candidates currently in development, including at least 8 in late-stage clinical trials. While clinical trials are underway, most of these treatments remain in the investigative phase.
The players
Apnimed
A biopharmaceutical company focused on the development of oral medicines to treat sleep apnea.
Shionogi
A pharmaceutical company researching treatments for infectious and chronic diseases, including respiratory conditions.
Mosanna Therapeutics
A biotech firm dedicated to developing novel pharmacotherapies for sleep apnea and related metabolic disorders.
FDA
The United States federal agency responsible for overseeing the safety and efficacy of medical products.
DelveInsight
A research and consulting firm that provides analysis on clinical trial pipelines and healthcare market trends.
The details
Companies are exploring various pharmacological pathways, including GLP-1 receptor agonists, cannabinoid receptor agonists, and carbonic anhydrase inhibitors. The pipeline strategy includes targeting specific biological mechanisms to potentially manage sleep-disordered breathing. Apnimed's AD109, for instance, is an oral combination therapy under FDA review that includes both aroxybutynin and atomoxetine.
Timeline
January 2025: FDA cleared the IND application for a Phase II trial of lorundrostat.
April 2025: Shionogi and Apnimed entered an agreement for the development of sulthiame.
June 2025: Mosanna Therapeutics raised 80 million USD in Series A funding.
July 2026: The FDA accepted the New Drug Application for Apnimed's AD109 for review.
February 28, 2027: The FDA target action date for AD109.
Health Landscape
This influx of new pharmacological candidates marks a significant expansion of the clinical pipeline currently navigating the established regulatory pathways. It represents a shift from a device-heavy market to one increasingly defined by personalized, pharmacologically driven treatment models.
While these developments suggest a broader range of future treatments, current patients should continue to follow established therapies as prescribed. It is worth discussing with your physician how emerging oral treatment research may eventually change the landscape for sleep apnea care.
The takeaway
The field of sleep apnea treatment is evolving to include more oral drug options that target specific biological mechanisms. Patients should stay informed about these pipeline developments and maintain consistent communication with their doctor regarding any new, approved options as they become available.
What happens next
The FDA is scheduled to reach a decision on the approval of Apnimed's AD109 by February 28, 2027.
Further reading
Learn more about the latest research and standard treatment methods in Sleep Disorders.
More information
View the report sample and research access for further details on current clinical trials.
Source note: This article includes information reported by The Manila times.
Live Poll
Will new pharmacological treatments lead to better long-term management for sleep apnea patients?
